MedPath

A POST MARKETING SURVEILLANCE STUDY TO EVALUATE THE SAFETY AND EFFICACYOF ORTHOHERB OI

Phase 4
Conditions
Health Condition 1: M172- Bilateral post-traumatic osteoarthritis of kneeHealth Condition 2: M170- Bilateral primary osteoarthritis of kneeHealth Condition 3: M179- Osteoarthritis of knee, unspecifiedHealth Condition 4: M06- Other rheumatoid arthritisHealth Condition 5: M173- Unilateral post-traumatic osteoarthritis of kneeHealth Condition 6: M171- Unilateral primary osteoarthritisof knee
Registration Number
CTRI/2021/07/034635
Lead Sponsor
Pankajakasthuri Herbals India Pvt Ltd
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Closed to Recruitment of Participants
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Age: 35 -70 years

2.Willing to applying Orthoherb oil externally at least one time per day for a continuous period of 6 months

3.Having one or more joint pain

4.Willing to enrol in study by signing Informed consent

Exclusion Criteria

1.Earlier participation in this study

2.Subjects using Orthoherb oil since more than two months

3.Pain is of acute onset or due to trauma/injury

4.Unable to respond properly for questionnaire or when a patient is too severely ill to answer the questions

Study & Design

Study Type
PMS
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1.Reconfirming the efficacy of Orthoherb oil in joint pain and disorders. <br/ ><br>2.Ensuring safety of Orthoherb oil on prolonged use. <br/ ><br>3.Incidence of adverse effects or adverse events in users of Orthoherb oil <br/ ><br>Timepoint: oth-baseline <br/ ><br>1st-first response to questionnaire and 2nd -response at the end of the study
Secondary Outcome Measures
NameTimeMethod
1.Assessing additional therapeutic benefits of Orthoherb oil. <br/ ><br>2.Reconsider the need of pharmaceutical modification of the product to increase patient compliance if required. <br/ ><br>Timepoint: oth-baseline <br/ ><br>1st-first response to questionnaire and 2nd -response at the end of the study
© Copyright 2025. All Rights Reserved by MedPath